H-Index
17
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

Annals
ISI-Home

Long term survival in a patient with malign pleuralmesothelioma after gemcitabine treatment

Ugur Coskun, Nazan Gunel, Yesim Yildirim

CaseRepClinPractRev 2003; 4(2):92-93

ID: 429040

Available online:

Published:


Background: Malign pleural mesothelioma is a chemoresistant tumor. Despite of advancement in chemoterapeutic agent, its prognosis remains poor.Case Report: Gemcitabine can be used as first line therapy in malign mesothelioma with a responce rate of 7% to 30%. Second line agents in this tumor are ineffective. We present a malign pleural mesothelioma (MPM) case treated with gemcitabine as a second line agent. Conclusions: Long term survival is achived with gemcitabine threapy in MPM.

Keywords: Mesothelioma, Gemcitabine, Survival



Back